Human immunodeficiency virus. Human immunodeficiency virus [HIV] disease
Conditions
Interventions
Intervention 1: Intervention group: They receive rTMS protocol in addition to routine treatment. The research was conducted in such a way that the subjects will be assessed by the Beck depression test
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: Insomnia and depression Ability to participate in therapy sessions At least diploma education age between 20 and 65 years Stay in Tehran Full consciousness and able to speak Persian Physical and mental preparation is necessary to answer the questions not having a specific mental illness before treatment (based on the patient's report)
Exclusion criteria
Exclusion criteria: Subject's unwillingness to participate or continue participating in research Getting malignancies Having autoimmune disorders Facing specific psychological crises during the stages of work Doing other psychological treatments Need to be re-hospitalized Seizures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anxiety and depression level. Timepoint: One week before the treatment and in the 5th and 10th weeks after the treatment and if the treatment continues until the 20th week. Method of measurement: To check depression, the Hamilton Depression Rating Scale (HDRS) questionnaire and its severity are also checked and recorded using the Beck depression measuring tool.;The quality of life. Timepoint: The mentioned form will be completed one week before the treatment and in the 5th and 10th weeks after the treatment and if the treatment continues until the 20th week. Method of measurement: by the sf 36 quality of life questionnaire, which has been confirmed in various Persian and English studies in terms of validity and reliability.;Sleep quality questionnaire score. Timepoint: The mentioned form will be completed one week before the treatment and in the 5th and 10th weeks after the treatment and if the treatment continues until the 20th week. Method of measurement: by the sleep quality questionnaire, which has been confirmed in various Persian and English studies in terms of validity and reliability. | — |
Secondary
| Measure | Time frame |
|---|---|
| CD3 and CD4 levels. Timepoint: before and 3 months after receiving repetitive brain magnetic stimulation (rTMS) treatment. Method of measurement: routine blood sample Test for surface counting CD3-CD4. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed Ali Dehghan Manshadi
Tehran University of Medical Sciences
Outcome results
None listed